09:47 AM EST - Aeterna Zentaris Inc : announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research. Aeterna Zentaris Inc
shares T.AEZ are trading down $0.02 at $0.66.
